Mainz Biomed (NASDAQ:MYNZ) just reported results for the fourth quarter of 2023.
- Mainz Biomed reported earnings per share of -24 cents. This was above the analyst estimate for EPS of -32 cents.
- The company reported revenue of $214,761.
- This was 20.46% worse than the analyst estimate for revenue of $270,000.